Cover news reporter Zhou Jiayi
On November 15th, the "8th Cord Blood Conference and Cord Blood Application and Quality Control Seminar" sponsored by the China Maternal and Child Health Association and hosted by the Cord Blood Application Professional Committee was held in Beijing. Through online live broadcast, the conference invited more than 70 experts and scholars in the field of cord blood transplantation research at home and abroad to conduct extensive and in-depth exchanges on cord blood transplantation, application and scientific research topics, and demonstrated the latest achievements in clinical practice and scientific research of cord blood.
It is reported that the conference was presided over by Wang Ji, vice chairman of the Cord Blood Application Professional Committee of the China Maternal and Child Health Association, and hospital managers, clinicians and researchers from all over the country in the fields of hematology, obstetrics, pediatrics, neonatology, rehabilitation and cell therapy attended the meeting online.
Cord blood is widely used in clinical applications More value remains to be tapped
Cord blood is the blood left in the umbilical cord and placenta of newborns, due to the rich hematopoietic stem cells, can be used for the treatment of more than 80 major diseases such as blood and immune system, the current global cord blood application has nearly 80,000 cases, the number of Chinese cord blood application cases more than 16,000 cases.
With the deepening of research, the clinical research of cord blood in the field of regenerative medicine has also achieved phased results, which will open the door to rehabilitation for more patients with difficult and serious diseases.
According to Liu Kaiyan, deputy director of the Institute of Hematology of Peking University and chairman of the Umbilical Cord Blood Application Committee, in pediatrics, cord blood treatment of congenital diseases, metabolic diseases, and hereditary immunodeficiency diseases has achieved very good results, but more in-depth research is needed in the treatment of methods and mechanisms in the treatment of bone marrow or peripheral blood diseases.
Wu Depei, chairman of the Hematology Branch of the Chinese Medical Association, said that cord blood can do a lot of scientific research, there are many unknowns waiting to be opened, whether basic or clinical, we have the responsibility and obligation to do better research on cord blood, and tap the greater value of cord blood from it.
More than 70 experts outline the "new direction" of cord blood application online
It is reported that this year's cord blood conference is divided into four discussion themes: "Introduction of the Asian Cord Blood Alliance", "Application of Cord Blood Transplantation in the Treatment of Childhood Diseases", "Cord Blood and Cord Blood Combined Transplantation for the Treatment of Blood System Diseases", and "Clinical Research Report on Cord Blood".
Professor Tokiko Nagamura-Inoue of the Institute of Medical Sciences of the University of Tokyo introduced the development process of the Asian Cord Blood Alliance, pointing out that because cord blood contains hematopoietic stem cells, immunomodulatory cells, etc., so that it has the potential of hematopoietic reconstruction, tissue repair and immunomodulation, the current application of global cord blood has been constantly changing, cord blood is not only used in transplantation, but also for the treatment of regenerative medicine, especially cerebral palsy and other diseases. Make cord blood an important resource for cell therapy.
Professor Young-Ho Lee of the Department of Pediatrics, Hanyang University Medical Center, Korea, introduced cord blood collection and clinical research during the new crown virus pneumonia. He summarized international clinical cases to demonstrate the initial effect of cord blood and umbilical cord blood-derived immune cells in the treatment of COVID-19 pneumonia and its complications ARDS, in which the Johns Hopkins University clinical study tried to use cord-blood-derived Treg cells to treat two cases of respiratory distress syndrome (ARDS) caused by new crown pneumonia.
Professor Sun Zimin of the Department of Hematology of the First Affiliated Hospital of the University of Science and Technology of China pointed out in the topic of "Non-blood Cord Blood Transplantation for Malignant Blood Diseases" that Cord Blood Transplantation in Asia shows a trend of increasing year by year, with more than 1380 cases in Japan every year, accounting for more than 50% of non-blood transplants; Cord blood transplantation in China is also on the rise, with more than 500 cord blood transplants in 2019. Professor Sun Zimin pointed out that cord blood transplantation has few complications, the recurrence rate is very low, and the treatment of adult malignant blood disease is very good. For the future development of cord blood hematopoietic stem cells, Professor Sun Zimin believes that in addition to being a very good source of high-quality cells, cord blood also has very good application prospects in tissue repair and organ reconstruction, and cord blood can not only be used for transplantation, but also for the treatment of other diseases.
Professor Chen Jia of the Department of Hematology of the First Affiliated Hospital of Soochow University introduced the clinical research results of haploid cord blood transplantation in various countries and the experience of the center in the topic of "Haploid-Cord Blood Transplantation Research Progress", he pointed out that haploid cord blood transplantation combines the advantages of haploid transplantation and cord blood transplantation, which can both inhibit recurrence and inhibit infection, which is a very promising transplantation method, and it is necessary to further confirm and study the mechanism through large-scale clinical research in the future.
Professor Zhai Xiaowen, Vice President of the Children's Hospital of Fudan University and Professor of the Department of Hematology, pointed out in the topic of "Application of Cord Blood Transplantation in Pediatric Immunodeficiency Diseases" that there are many kinds of congenital immune diseases in children, and most children with primary immunodeficiency diseases are young and light in weight, which is suitable for cord blood transplantation. Cord blood treatment has a good future, and continuous efforts should be made to improve the success rate of cord blood transplantation to benefit more sick children.
Professor Chen Jing of the Department of Hematology/Oncology of Shanghai Children's Medical Center pointed out in the topic of "Application of Cord Blood in Congenital Metabolic Diseases" that there are more than 500 congenital genetic metabolic diseases, most of which lack radical cures, of which about 20 kinds of genetic metabolic diseases can be treated by hematopoietic stem cell transplantation. Cord blood stem cells have obvious advantages for improved enzyme activity and are a suitable graft choice, while early diagnosis is critical to improving efficacy and requires enhanced collaboration between multidisciplinary physicians. For mucopolysaccharides, compared with enzyme substitution treatments, there is an international trend to recommend early transplant treatment. Shanghai Children's Medical Center has treated more than 100 multidisciplinary transplants with a survival rate of 95%, and now more and more cord blood stem cells are used for treatment.
Professor Sun Yuan, medical director of Beijing Kyoto Children's Hospital and department of hematology and oncology, said in the topic of "Cord Blood Transplantation for the Treatment of Pyruvate Kinase Deficiency in Children": "The prevalence of pyruvate kinase deficiency is very low, and we found that many of these diseases must benefit from cord blood transplantation, showing the outstanding advantages of cord blood." For genetic diseases, especially for the quality of life and long-term survival of children, cord blood application has very clear advantages.
Peking University Third Hospital Reproductive Center Key Laboratory Zhu Xiaohui, Professor Yang Ping of the Department of Hematology made a "embryo diagnostic technology combined with cord blood transfer technology to treat mucopolysaccharide case report" sharing, at present, China can already pass the preimplantation genetic diagnosis technology, in the family to carry out single gene genetic disease pathogenic gene testing at the same time, embryo HLA classification, select the embryo that is not diseased and is fully compatible with the child's matching into the mother, this detection method can allow couples to obtain healthy offspring, At the same time, newborn umbilical cord blood hematopoietic stem cells can also be treated by stem cell transplantation.
In terms of basic research, Professor Chen Juan of west China Second Hospital of Sichuan University introduced that in the rat model of hypoxic ischemic injury, transplantation of umbilical cord blood mononuclear cells and umbilical cord mesenchymal stem cells can promote the recovery of rat spatial memory, reduce apoptosis, and reduce the number of astrocytes, so the transplantation of these two cells is a good alternative therapy for the treatment of neonatal hypoxic-ischemic encephalopathy, which has great value.
<b>[If you have a news thread, please report to us, once adopted, there is a fee reward.] WeChat attention: ihxdsb, QQ: 3386405712].</b>